KOSPIBiotech & Pharma302440

SK Bioscience

₩38,500▼ 3.51%2026-11-18 close
Market Cap
₩3T
Turnover
₩3B
Volume
80K
Shares out.
78.5M
PER
—
PBR
1.8×
EPS
-₩1,260
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Narrowing losses and IDT growth; sustained profit is the test

SK bioscience narrowed its operating loss in the third quarter of 2026 and returned controlling-shareholder net income to profit, but operating losses have run for five straight quarters since the third quarter of 2025, so sustained profitability is the next test.

  1. 1

    Revenue reached KRW 651.4 billion in 2025, up 143.5% from the prior year and the largest year in the 2022-2025 span, recovering from the KRW 267.5 billion low in 2024.

  2. 2

    The third-quarter 2026 operating loss narrowed to KRW 11.2 billion from a year earlier, and controlling-shareholder net income of KRW 10.5 billion turned positive from the prior quarter's loss.

  3. 3

    Controlling-shareholder net losses over the last four quarters total KRW 98.6 billion, and the company recorded operating losses for three consecutive years from 2023 to 2025.

  4. 4

    The company secured 2.7 million doses in the 2026-2027 national influenza procurement, the largest volume across the last four seasons, under a KRW 23.9 billion contract.

  5. 5

    Subsidiary IDT Biologika reported third-quarter 2026 revenue of KRW 113.1 billion and cumulative operating profit of KRW 22.3 billion, according to provisional figures disclosed on November 5, 2026, and it is central to the consolidated improvement.

02

Business structure

SK bioscience runs three businesses: developing and manufacturing its own vaccines, distributing vaccines from partners, and operating contract development and manufacturing through its subsidiary.

Its cell-culture seasonal flu vaccine Skycellflu became the first cell-culture influenza vaccine to receive WHO prequalification, and its varicella vaccine SKYVaricella has been expanding shipments through the Pan American Health Organization (PAHO), including to Colombia.

Own-vaccine revenue in the first quarter of 2026 was reported at KRW 20.7 billion in total, covering flu at KRW 4.1 billion, shingles at KRW 12.2 billion and varicella at KRW 4.4 billion.

Distribution under the Sanofi partnership, including the RSV antibody injection Beyfortus and the hexavalent vaccine Hexaxim, grew in the third quarter of 2026. The German CDMO IDT Biologika, acquired in 2024, is a central pillar of consolidated results.

IDT's third-quarter 2026 revenue of KRW 113.1 billion rose 21% year on year, and operating profit was reported at KRW 9.6 billion, based on provisional figures disclosed on November 5, 2026. IDT's profitability depends on production volumes from major clients and the share of higher-margin contracts.

Domestically, government influenza procurement is the main revenue source, while overseas public procurement is widening through PAHO and UNICEF. The business rests on two pillars, own-vaccine sales and CDMO revenue.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩150.8B-₩19.4B−12.8%
2025Q4₩184.2B-₩51.6B−28.0%
2026Q1₩168.6B-₩44.5B−26.4%
2026Q2₩155.7B-₩15.7B−10.1%
2026Q3₩182.4B-₩11.2B−6.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩456.7B₩115B₩122.5B25.2%7.0%23.0%
2023₩369.5B-₩12B₩22.3B−3.2%1.3%8.7%
2024₩267.5B-₩138.4B-₩53.9B−51.7%−3.0%40.6%
2025₩651.4B-₩123.5B-₩57.4B−19.0%−3.2%45.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On a DART-reported annual basis, revenue fell from KRW 456.7 billion in 2022 to KRW 369.5 billion in 2023, down 19.1%, and then to KRW 267.5 billion in 2024, down 27.6%, before jumping to KRW 651.4 billion in 2025, up 143.5%. Among 2022-2025, 2025 was the largest year and 2024 was the smallest.

Operating profit of KRW 115 billion in 2022 turned into an operating loss of KRW 12 billion in 2023, widened to an operating loss of KRW 138.4 billion in 2024, and then narrowed to an operating loss of KRW 123.5 billion in 2025. The company recorded losses for three consecutive years from 2023 to 2025.

The operating margin moved from 25.2% in 2022 to -3.2% in 2023, -51.7% in 2024 and -19.0% in 2025, and the deepest margin loss came in the year with the smallest revenue.

Net income attributable to controlling shareholders fell from KRW 122.5 billion in 2022 to KRW 22.3 billion in 2023, down 81.8%, turned into a loss of KRW 53.9 billion in 2024, and widened to a loss of KRW 57.4 billion in 2025.

Net income including non-controlling interests was a loss of KRW 50.1 billion in 2024 and a loss of KRW 56.2 billion in 2025, a separate figure from controlling-shareholder results.

Quarterly operating losses moved from KRW 19.4 billion in the third quarter of 2025 to KRW 51.6 billion in the fourth quarter, then narrowed to KRW 44.5 billion, KRW 15.7 billion and KRW 11.2 billion across the first three quarters of 2026.

Revenue peaked at KRW 184.2 billion in the fourth quarter of 2025, fell to KRW 168.6 billion and KRW 155.7 billion in the first two quarters of 2026, and recovered to KRW 182.4 billion in the third quarter of 2026, up 21.0% from a year earlier.

Controlling-shareholder net income of KRW 10.5 billion in the third quarter of 2026 turned positive from a KRW 17.9 billion loss in the prior quarter, though it was down 57.0% from KRW 24.5 billion a year earlier. Controlling-shareholder net losses over the last four quarters total KRW 98.6 billion.

Reported drivers of the first-quarter 2026 loss increase were higher R&D spending, Songdo-related costs, higher depreciation and the end of a prior-year inventory valuation reversal on flu vaccines.

05

Industry analysis

The domestic vaccine industry has seen weaker results since demand fell after COVID-19, and companies are reshaping their models through contract development and manufacturing, overseas production sites and exports of their own vaccines.

SK bioscience secured a German production site by acquiring IDT Biologika and has widened overseas public procurement for its own vaccines from PAHO to UNICEF. Government national immunization program procurement is the main channel for domestic flu vaccines.

Total influenza procurement for the 2026-2027 season is 12.33 million doses, of which SK bioscience secured 2.7 million, the largest share across the last four seasons. Total procurement volume rose from 11.21 million doses over the same four seasons, while the procurement unit price fell 16.9% over four years.

Reporting described the larger volume as a buffer for revenue during a period of falling prices. Competitor allocations in the same season were 2.66 million doses for GC Biopharma, 2.25 million for Sanofi-Aventis Korea, 1.9 million for Korea Vaccine, and 1.77 million for Boryung BioPharma.

Some observers noted that the contract's contribution to overall profit is limited, with R&D and depreciation costs weighing more. On the technology side, cell-culture flu vaccines are reported to have shorter production times and lower risk of viral mutation during manufacturing.

The seasonal flu vaccine market for older adults was estimated at about USD 459 million per year in a February 2026 report.

06

Outlook

The company's business schedule, as disclosed and reported, can be grouped into a few items. The 2026-2027 influenza supply contract was signed on June 23, 2026, and runs through June 30, 2027. Reporting said flu vaccine revenue from this contract would be reflected in fourth-quarter 2026 results.

UNICEF designated SK bioscience as a 2026 influenza vaccine supplier, with a single-supplier role for Southern Hemisphere volumes and a major-supplier role for Northern Hemisphere volumes. The plan is to supply about 640,000 doses within the year, with Northern Hemisphere shipments beginning in September 2026.

In Europe, the company and IDT Biologika joined Australia's Vaxxas in a consortium selected for phase one of an EU next-generation vaccine initiative. Phase one funding is EUR 12.9 million, and funding could expand to as much as EUR 225 million if the program advances to phase three and beyond.

In the pipeline, the next-generation pneumococcal vaccine GBP410, co-developed with Sanofi, is in global phase three trials, and a pan-sarbecovirus vaccine supported by CEPI has entered global clinical testing.

The RSV antibody candidate RSM01 received a pediatric phase 1b trial application to South Africa's regulator in August 2026. The company plans to improve production efficiency at IDT, expand higher-value contracts and strengthen its client portfolio in strategic regions such as North America and Japan.

Investment in research and production infrastructure at Songdo continues, so how these costs flow through operating expenses is a point to track.

07

Valuation

PER
—
PBR
1.8×
ROE
-5.6%
EPS
-₩1,260
BPS
₩21,714
Dividend per share
₩0

The price-to-book ratio sits above 1x, which means the shares trade at a premium to the book value attributable to controlling shareholders. Because controlling-shareholder net losses over the last four quarters total KRW 98.6 billion, the price-to-earnings ratio cannot be calculated.

Without an earnings-based multiple, the asset-based multiple and improvement in operating indicators are the reference points. Dividends are not being paid at a level that would provide a shareholder-return signal.

Results alternated between profit and loss on an annual basis over recent years, so valuation interpretation depends on whether the move from losses to profit is sustained.

Controlling-shareholder net income turning positive in the third quarter of 2026 is a change in direction, but a single quarter is not enough to judge earnings capacity.

After three consecutive years of operating losses from 2023 to 2025 and net losses in 2024 and 2025, it is also worth tracking how total equity changes. Reading the valuation as a gauge of the gap between market expectations and the pace of earnings recovery is closer to the facts.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Smaller operating losses and a quarterly profit turn

Third-quarter 2026 operating loss narrowed to KRW 11.2 billion from a year earlier, reported as the smallest loss in 11 quarters since the fourth quarter of 2023. Controlling-shareholder net income of KRW 10.5 billion turned positive from a KRW 17.9 billion loss in the prior quarter. Revenue recovered to KRW 182.4 billion, reversing two quarters of decline.

IDT growth is supporting consolidated results

Subsidiary IDT Biologika reported third-quarter 2026 revenue of KRW 113.1 billion, up 21% year on year, and operating profit of KRW 9.6 billion, up about 66%, based on provisional figures disclosed on November 5, 2026. Cumulative operating profit reached KRW 22.3 billion, up 56% from a year earlier.

The company attributed this to higher production volumes at major clients and a larger share of higher-margin sales.

Overseas expansion through public procurement and European funding

In June 2026, SK bioscience was designated a UNICEF influenza vaccine supplier, adding to its PAHO channel across the two major global public procurement markets.

The company was selected for phase one of an EU next-generation vaccine initiative with EUR 12.9 million in funding, which could expand to as much as EUR 225 million. The company described this as its first project won from a European public health authority.

09

Bear factors

Three straight years of operating losses and cumulative net losses

Operating losses continued for three consecutive years from 2023 to 2025, with the 2025 operating loss at KRW 123.5 billion. Controlling-shareholder net losses were KRW 53.9 billion in 2024 and KRW 57.4 billion in 2025.

Controlling-shareholder net losses over the last four quarters total KRW 98.6 billion, and operating losses persisted through the third quarter of 2026 even as net income turned positive.

Rising costs and the end of an inventory reversal

The first-quarter 2026 operating loss widened to KRW 44.5 billion, with reported drivers including higher R&D costs, Songdo-related expenses and depreciation, along with the end of a prior-year inventory valuation reversal on flu vaccines. Continued research and production investment keeps fixed-cost pressure in place.

Quarterly revenue also fell to KRW 168.6 billion in the first quarter and KRW 155.7 billion in the second quarter of 2026, which underlines earnings volatility.

Falling procurement prices and competing volumes

Domestic influenza procurement unit prices have fallen 16.9% over four years, and reporting put the unit price of this contract at KRW 8,851 per dose. Competitors including GC Biopharma, Sanofi-Aventis Korea, Korea Vaccine and Boryung BioPharma also secured substantial volumes in the same season. Some reporting suggested the contract's contribution to overall profit would be limited.

10

Risk factors

Clinical and development risk

Several pipeline programs are advancing at once, including the GBP410 pneumococcal vaccine in global phase three trials, a pan-sarbecovirus vaccine in clinical testing and the RSM01 RSV antibody in a planned phase 1b trial.

If clinical results disappoint or timelines slip, the period for recovering research spending lengthens. Because R&D costs are rising, the pace of these programs feeds directly into profit and loss.

Public procurement pricing and bidding risk

Domestic influenza procurement is a competitive bidding structure, so winning prices shape revenue and profitability. With unit prices down 16.9% over four years, relying on volume alone to protect revenue has limits.

Overseas supply through UNICEF and PAHO also depends on bidding outcomes and each country's vaccination schedule, so volumes can shift.

Dependence on a subsidiary and overseas business volatility

Improvement in consolidated results depends heavily on growth at IDT Biologika, the German CDMO subsidiary. IDT's profitability depends on production volumes and contract structure at major clients, so a change in one client's volume can pass straight through to consolidated profit and loss. Overseas subsidiary results are also affected by euro translation and local regulatory conditions.

11

What to watch next

  1. By the end of December 2026

    Track progress on the UNICEF influenza supply, about 640,000 doses within the year. Whether overseas public procurement revenue continues will indicate the trend in own-vaccine sales.

  2. January to February 2027

    The fourth-quarter 2026 results will show how much influenza NIP revenue was reflected in the quarter and whether the narrowing operating loss continues. The key question is whether the third-quarter profit turn repeats on a quarterly basis.

  3. By March 31, 2027

    The 2026 annual report will show full-year operating margin, debt ratio and changes in total equity. It will serve as the next reference against the 2025 disclosed results.

  4. Ongoing disclosures from November 2026

    Track progress of the GBP410 global phase three trial and whether the RSM01 phase 1b trial begins. Pipeline progress affects the R&D cost burden and the potential for technology deals.

  5. June 30, 2027

    This is the end of the 2026-2027 influenza supply contract period. Next season's procurement volume and unit price changes will show how the 2027 business plan is shaped.

12

Overall view

SK bioscience's disclosed results show that revenue jumped in 2025 after the 2024 low, but operating losses persisted for three consecutive years from 2023 to 2025, and that is the central issue.

In the third quarter of 2026, the operating loss narrowed to KRW 11.2 billion and controlling-shareholder net income turned positive at KRW 10.5 billion, signaling a change in direction. Growth at subsidiary IDT Biologika, own-vaccine sales and wins in UNICEF and EU projects are cited as support for the improvement.

On the other side, controlling-shareholder net losses over the last four quarters total KRW 98.6 billion, and higher R&D and selling costs widened the loss in the first quarter of 2026, so the earnings structure cannot yet be called stable.

Declining procurement prices, more competing volume and clinical development risk should be weighed alongside. Valuation reads differently depending on how quickly the move from losses to profit proceeds and how total equity changes.

The next checkpoints are fourth-quarter 2026 results and the operating margin in the 2026 annual report, which are factual reference points rather than a judgment on the investment.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. vegannews.co.kr
  2. betanews.net
  3. view.asiae.co.kr
  4. newspim.com
  5. view.asiae.co.kr
  6. m.news.nate.com
  7. news.mtn.co.kr
  8. mydaily.co.kr
  9. alphabiz.co.kr
  10. hankyung.com
  11. bloter.net
  12. thebionews.net
  13. news.nate.com
  14. getnews.co.kr
  15. mt.co.kr
  16. hankyung.com
  17. m.news.nate.com
  18. m.news.nate.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis